Olux-E Foam Now Approved
NEW Olux-E Foam delivers Class I steroid power in a silky foam uniquely designed for the body.
OLUX-E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. Treatment should be limited to 2 consecutive weeks and patients should not use greater than 50 grams per week.
OLUX-E Foam has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
The pooled incidence of local adverse reactions in trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with OLUX-E Foam was 1.9% for application site atrophy and 1.6% for application site reaction.
